Pathogenesis of Thromboembolism and Endovascular Management

Sasan Behravesh, Peter Hoang, Alisha Nanda, Alex Wallace, Rahul A. Sheth, Amy R. Deipolyi, Adnan Memic, Sailendra Naidu, Rahmi Oklu

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Venous thromboembolism (VTE), a disease that includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with high mortality, morbidity, and costs. It can result in long-term complications that include postthrombotic syndrome (PTS) adding to its morbidity. VTE affects 1/1000 patients, costs $13.5 billion annually to treat, and claims 100,000 lives annually in the US. The current standard of care for VTE is anticoagulation, though thrombolysis may be performed in patients with PE and threatened limb. This review discusses pathogenesis and medical treatment of VTE and then focuses on endovascular treatment modalities. Mechanical- and catheter-directed thrombolysis (CDT) is discussed, as well as patient selection criteria, and complications. The first prospective study (CaVenT) comparing CDT with anticoagulation alone in acute DVT, despite study shortcomings, corroborates the existing literature indicating improved outcomes with CDT. The potential of the ongoing prospective, multicenter, randomized ATTRACT trial is also highlighted.

Original languageEnglish (US)
Article number3039713
JournalThrombosis
Volume2017
DOIs
StatePublished - Jan 1 2017

Fingerprint

Thromboembolism
Venous Thromboembolism
Catheters
Pulmonary Embolism
Venous Thrombosis
Patient Selection
Postthrombotic Syndrome
Morbidity
Costs and Cost Analysis
Standard of Care
Extremities
Prospective Studies
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Behravesh, S., Hoang, P., Nanda, A., Wallace, A., Sheth, R. A., Deipolyi, A. R., ... Oklu, R. (2017). Pathogenesis of Thromboembolism and Endovascular Management. Thrombosis, 2017, [3039713]. https://doi.org/10.1155/2017/3039713

Pathogenesis of Thromboembolism and Endovascular Management. / Behravesh, Sasan; Hoang, Peter; Nanda, Alisha; Wallace, Alex; Sheth, Rahul A.; Deipolyi, Amy R.; Memic, Adnan; Naidu, Sailendra; Oklu, Rahmi.

In: Thrombosis, Vol. 2017, 3039713, 01.01.2017.

Research output: Contribution to journalReview article

Behravesh, S, Hoang, P, Nanda, A, Wallace, A, Sheth, RA, Deipolyi, AR, Memic, A, Naidu, S & Oklu, R 2017, 'Pathogenesis of Thromboembolism and Endovascular Management', Thrombosis, vol. 2017, 3039713. https://doi.org/10.1155/2017/3039713
Behravesh S, Hoang P, Nanda A, Wallace A, Sheth RA, Deipolyi AR et al. Pathogenesis of Thromboembolism and Endovascular Management. Thrombosis. 2017 Jan 1;2017. 3039713. https://doi.org/10.1155/2017/3039713
Behravesh, Sasan ; Hoang, Peter ; Nanda, Alisha ; Wallace, Alex ; Sheth, Rahul A. ; Deipolyi, Amy R. ; Memic, Adnan ; Naidu, Sailendra ; Oklu, Rahmi. / Pathogenesis of Thromboembolism and Endovascular Management. In: Thrombosis. 2017 ; Vol. 2017.
@article{4bca9cb2dda248668f56fb73dcc8d6f2,
title = "Pathogenesis of Thromboembolism and Endovascular Management",
abstract = "Venous thromboembolism (VTE), a disease that includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with high mortality, morbidity, and costs. It can result in long-term complications that include postthrombotic syndrome (PTS) adding to its morbidity. VTE affects 1/1000 patients, costs $13.5 billion annually to treat, and claims 100,000 lives annually in the US. The current standard of care for VTE is anticoagulation, though thrombolysis may be performed in patients with PE and threatened limb. This review discusses pathogenesis and medical treatment of VTE and then focuses on endovascular treatment modalities. Mechanical- and catheter-directed thrombolysis (CDT) is discussed, as well as patient selection criteria, and complications. The first prospective study (CaVenT) comparing CDT with anticoagulation alone in acute DVT, despite study shortcomings, corroborates the existing literature indicating improved outcomes with CDT. The potential of the ongoing prospective, multicenter, randomized ATTRACT trial is also highlighted.",
author = "Sasan Behravesh and Peter Hoang and Alisha Nanda and Alex Wallace and Sheth, {Rahul A.} and Deipolyi, {Amy R.} and Adnan Memic and Sailendra Naidu and Rahmi Oklu",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/3039713",
language = "English (US)",
volume = "2017",
journal = "Thrombosis",
issn = "2090-1488",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Pathogenesis of Thromboembolism and Endovascular Management

AU - Behravesh, Sasan

AU - Hoang, Peter

AU - Nanda, Alisha

AU - Wallace, Alex

AU - Sheth, Rahul A.

AU - Deipolyi, Amy R.

AU - Memic, Adnan

AU - Naidu, Sailendra

AU - Oklu, Rahmi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Venous thromboembolism (VTE), a disease that includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with high mortality, morbidity, and costs. It can result in long-term complications that include postthrombotic syndrome (PTS) adding to its morbidity. VTE affects 1/1000 patients, costs $13.5 billion annually to treat, and claims 100,000 lives annually in the US. The current standard of care for VTE is anticoagulation, though thrombolysis may be performed in patients with PE and threatened limb. This review discusses pathogenesis and medical treatment of VTE and then focuses on endovascular treatment modalities. Mechanical- and catheter-directed thrombolysis (CDT) is discussed, as well as patient selection criteria, and complications. The first prospective study (CaVenT) comparing CDT with anticoagulation alone in acute DVT, despite study shortcomings, corroborates the existing literature indicating improved outcomes with CDT. The potential of the ongoing prospective, multicenter, randomized ATTRACT trial is also highlighted.

AB - Venous thromboembolism (VTE), a disease that includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with high mortality, morbidity, and costs. It can result in long-term complications that include postthrombotic syndrome (PTS) adding to its morbidity. VTE affects 1/1000 patients, costs $13.5 billion annually to treat, and claims 100,000 lives annually in the US. The current standard of care for VTE is anticoagulation, though thrombolysis may be performed in patients with PE and threatened limb. This review discusses pathogenesis and medical treatment of VTE and then focuses on endovascular treatment modalities. Mechanical- and catheter-directed thrombolysis (CDT) is discussed, as well as patient selection criteria, and complications. The first prospective study (CaVenT) comparing CDT with anticoagulation alone in acute DVT, despite study shortcomings, corroborates the existing literature indicating improved outcomes with CDT. The potential of the ongoing prospective, multicenter, randomized ATTRACT trial is also highlighted.

UR - http://www.scopus.com/inward/record.url?scp=85038625950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038625950&partnerID=8YFLogxK

U2 - 10.1155/2017/3039713

DO - 10.1155/2017/3039713

M3 - Review article

AN - SCOPUS:85038625950

VL - 2017

JO - Thrombosis

JF - Thrombosis

SN - 2090-1488

M1 - 3039713

ER -